NOCIL Ltd (NOCIL) Growth Catalysts - Q1 FY27 (Jun-26)
8 growth catalysts flagged by management, 1 new in the recent quarters, 2 no longer discussed.
Reported base: Revenue from operations Rs 403 crores, +20% YoY; volume +9% YoY; EBITDA Rs 45 crores, margin 11.2%.
Growth catalysts
Pilflex 13 anti-dumping duty
DGTR findings for Pilflex 13 and 4ADPA remain pending; mgmt expects Pilflex 13 findings in the next month or so, with possible business effects dependent on the outcome. Pilflex 13 has a positive DGTR final recommendation, but implementation depends on Central Government approval, which remains discretionary. Mgmt said the outcome may come by end-September; if notified, ADD would cover 25% to 30% of top line, excluding TDQ.
Quantum: 25% to 30% of top line · Timeline: end of September · Rubber chemicals · Regulatory
Discussed on the earnings calls of Jun-26, Mar-26, Dec-25.
Full-year volume growth
Mgmt expects around 10% volume growth in FY27 versus FY26, with operating leverage also supporting its full-year outlook; it said the growth expectation had not been scaled down.
Quantum: 3% to 4% · Timeline: FY27 · Rubber chemicals · Customer/contract
Discussed on the earnings calls of Jun-26, Mar-26, Dec-25.
6 more growth catalysts on the Stocksigma ELITE plan.
Guidance & timelines
- TDQ revenues: There will be revenues coming in this year (Timeline: FY27)
- FY27 volume growth: 10% growth rate versus FY26 (Timeline: FY27)
4 more guidance items on ELITE.